Article Text

Download PDFPDF
A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium
  1. A L Young1,
  2. G Y S Leung1,
  3. A K K Wong1,
  4. L L Cheng1,2,
  5. D S C Lam1
  1. 1Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, People’s Republic of China
  2. 2Alice Ho Miu Ling Nethersole Hospital, Tai Po, NT, Hong Kong, People’s Republic of China
  1. Correspondence to: Dr A L Young Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong; asmyoungnetvigator.com

Abstract

Background: Mitomycin C (MMC) and limbal conjunctival autograft (LCAU) are two known useful adjuvants in the prevention of pterygial recurrence. This study was conducted to compare the outcome of these two treatments.

Methods: Prospective study on consecutive cases of primary pterygium (February 2001 to March 2002) randomised into two adjuvant groups: (1) intraoperative 0.02% MMC for 5 minutes or (2) LCAU. Patients were followed for recurrence (defined as fibrovascular tissue invading the cornea >1.5mm) and complications for a period of one year.

Results: 115 eyes in 114 patients who completed the study were randomised to receive MMC (n = 63) and LCAU (n = 52). There were 10 recurrences (15.9%) in the MMC group and only one recurrence (1.9%) in the LCAU group. There was a statistically significant difference in the recurrence rate between the two groups (p = 0.04). There were a total of three conjunctival cysts, three symblephara, one granuloma, and one dellen. No other visually significant complications were encountered in either group.

Conclusion: Although LCAU resulted in better one year success rates, it is technically more difficult and inapplicable in cases with previous limbal disturbance. Simple excision followed by MMC or LCAU are both safe and acceptable adjuvants for pterygium excision. Choice of adjuvant should be carefully made based on assessment of recurrence risk, local practices, and surgeon’s expertise.

  • CG, conjunctival graft
  • LCAU, limbal conjunctival autograft
  • MMC, mitomycin C
  • pterygium
  • conjunctival limbal autograft
  • mitomycin C
  • CG, conjunctival graft
  • LCAU, limbal conjunctival autograft
  • MMC, mitomycin C
  • pterygium
  • conjunctival limbal autograft
  • mitomycin C

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Financial support: Supported in part by Action for Vision (AFV) Eye Foundation, Hong Kong

  • Financial and propriety interest: none

Linked Articles

  • BJO at a glance
    Creig Hoyt